Janney Montgomery Scott’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-11,200
| Closed | -$68K | – | 2470 |
|
|
2021
Q3 | $68K | Buy |
+11,200
| New | +$69.8K | ﹤0.01% | 2268 |
|
|
2020
Q1 | – | Sell |
-10,500
| Closed | -$217K | – | 2146 |
|
|
2019
Q4 | $217K | Buy |
+10,500
| New | +$177K | ﹤0.01% | 1886 |
|
|
2018
Q4 | – | Sell |
-23,015
| Closed | -$431K | – | 2101 |
|
|
2018
Q3 | $431K | Sell |
23,015
-1,700
| -7% | -$39.1K | ﹤0.01% | 1517 |
|
|
2018
Q2 | $639K | Buy |
24,715
+1,825
| +8% | +$47.4K | 0.01% | 1255 |
|
|
2018
Q1 | $513K | Buy |
22,890
+600
| +3% | +$14.6K | 0.01% | 1322 |
|
|
2017
Q4 | $558K | Buy |
22,290
+3,245
| +17% | +$79.5K | 0.01% | 1251 |
|
|
2017
Q3 | $461K | Buy |
19,045
+1,075
| +6% | +$25.3K | 0.01% | 1300 |
|
|
2017
Q2 | $363K | Buy |
17,970
+4,395
| +32% | +$91.5K | ﹤0.01% | 1347 |
|
|
2017
Q1 | $365K | Buy |
13,575
+3,200
| +31% | +$65.3K | ﹤0.01% | 1319 |
|
|
2016
Q4 | $197K | Sell |
10,375
-350
| -3% | -$6.69K | ﹤0.01% | 1549 |
|
|
2016
Q3 | $210K | Buy |
+10,725
| New | +$181K | ﹤0.01% | 1375 |
|
Janney Montgomery Scott's FLXN Position: Q4 2021 in Review
Janney Montgomery Scott sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 11,200 shares — an estimated $68K sold.
Janney Montgomery Scott first reported a position in FLXN in Q3 2016 and held it in 11 quarters. The position peaked at $639K in Q2 2018. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- Janney Montgomery Scott reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- Janney Montgomery Scott sold 11,200 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $68K.
- Janney Montgomery Scott first reported a position in Flexion Therapeutics, Inc. in Q3 2016 and held it in 11 quarters.
- Janney Montgomery Scott's Flexion Therapeutics, Inc. position peaked at $639K in Q2 2018.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on Janney Montgomery Scott's 13F filing for Q4 2021, filed 27 Jan 2022.